Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADHAND
2022-502653-34-01Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 4, randomised, double-blind trial in atopic hand eczema (AHE) and atopic dermatitis (AD) comparing Tralokinumab 300 mg Q2W with Placebo Q2W (2 arms). Primary endpoint: Investigator's Global Assessment for Atopic Hand Eczema (IGA-AHE) 0 or 1 at Week 16. Started May 2024; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic hand eczema (AHE)atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-502653-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502653-34-01.